Review of NICE Technology Appraisal Guidance No.68; The clinical effectiveness and cost effectiveness of photodynamic therapy for age-related macular degeneration, No.155; Pegaptanib and ranibizumab for the treatment of age-related macular degeneration, and No.294; Aflibercept solution for injection for treating wet age related macular degeneration

Proposal to move the existing guidance to the static list

The planned date for review of the above guidance was February 2014.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

There is currently little evidence that would lead to a change in the existing recommendations made in TA68, TA155 and TA294.  Consequently we propose that all three pieces of guidance should move to the static list of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted. 

May 2014

Attachments